iCardiac CEO, Alex Zapesochny, Honored with PharmaVOICE 100 Selection
The list recognizes the most inspiring leaders in the life sciences industry
August 3, 2016, Rochester, N.Y.—iCardiac Technologies, Inc., a market and innovation leader in cardiac safety and respiratory studies, has announced that its CEO, Alex Zapesochny, has been named to the prestigious PharmaVOICE 100 list, which honors the most inspiring individuals in the life sciences industry.
Zapesochny was recognized for his leadership in the development of new and innovative ways of conducting more precise and efficient cardiac safety testing of drugs, including iCardiac’s High Precision QT and Early Precision QT methodologies.
Now in its 12th year, the PharmaVOICE 100, published by PharmaVOICE magazine, celebrates exceptional professionals in the life sciences industry who provide inspiration to their peers, colleagues, and companies through their innovative and impactful approaches to addressing the industry’s challenges.
Since co-founding iCardiac in 2006, Zapesochny has played a critical role in building the company and ensuring that its advanced technology gained acceptance in the industry. iCardiac’s cardiac safety assessment methodology now has set a new standard for precision and accuracy in all phases of clinical trials. The company, which has grown to 165 people, currently serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms.
“It is a great honor to be recognized alongside inspiring leaders in the life sciences industry,” Zapesochny said. “It takes a team to drive change, and this award is a testament to the iCardiac team’s unwavering commitment to developing innovative technologies that have resulted in an industrywide shift in the way cardiac safety is carried out in clinical trials.”
“This must-read issue has become one of the most-anticipated and highly regarded publications of the year, and it is our great pleasure to showcase the 100 men and women who are demonstrating inspired leadership, innovating across the ecosystem, creating transformative change, disrupting the status quo, and building relationships to position the industry in the best way possible to serve the ultimate stakeholders: patients,” said Taren Grom, Editor and Co-founder of PharmaVOICE.
About iCardiac Technologies:
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for cardiac safety and respiratory services. Its high precision cardiac safety assessment methodology has set a new standard for precision and accuracy in all phases of clinical trials. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit: www.icardiac.com.